CAD 0.03
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 38.26 Thousand CAD | -86.77% |
2022 | 289.26 Thousand CAD | 255.3% |
2021 | 81.41 Thousand CAD | 13.28% |
2020 | 71.87 Thousand CAD | 94.66% |
2019 | 36.92 Thousand CAD | 31.24% |
2018 | 28.13 Thousand CAD | 695.39% |
2017 | 3537.00 CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 63.6 Thousand CAD | 10.88% |
2024 Q1 | 57.36 Thousand CAD | 49.93% |
2023 Q3 | 27.4 Thousand CAD | 56.5% |
2023 FY | 38.26 Thousand CAD | -86.77% |
2023 Q4 | 38.26 Thousand CAD | 39.61% |
2023 Q2 | 17.51 Thousand CAD | -93.05% |
2023 Q1 | 252.12 Thousand CAD | -12.84% |
2022 Q3 | 12.45 Thousand CAD | 24.11% |
2022 FY | 289.26 Thousand CAD | 255.3% |
2022 Q1 | 32.64 Thousand CAD | -59.9% |
2022 Q2 | 10.03 Thousand CAD | -69.26% |
2022 Q4 | 289.26 Thousand CAD | 2222.33% |
2021 Q2 | 15.25 Thousand CAD | -3.01% |
2021 Q1 | 15.72 Thousand CAD | -78.12% |
2021 Q4 | 81.41 Thousand CAD | 325.86% |
2021 Q3 | 19.11 Thousand CAD | 25.34% |
2021 FY | 81.41 Thousand CAD | 13.28% |
2020 Q1 | 35.9 Thousand CAD | -2.75% |
2020 FY | 71.87 Thousand CAD | 94.66% |
2020 Q4 | 71.87 Thousand CAD | 122.99% |
2020 Q3 | 32.23 Thousand CAD | -15.5% |
2020 Q2 | 38.14 Thousand CAD | 6.22% |
2019 FY | 36.92 Thousand CAD | 31.24% |
2019 Q1 | 8586.00 CAD | -69.48% |
2019 Q2 | 26.32 Thousand CAD | 206.57% |
2019 Q4 | 36.92 Thousand CAD | 841.89% |
2019 Q3 | 3920.00 CAD | -85.11% |
2018 FY | 28.13 Thousand CAD | 695.39% |
2018 Q1 | - CAD | 0.0% |
2018 Q4 | 28.13 Thousand CAD | 0.0% |
2017 FY | 3537.00 CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AI/ML Innovations Inc. | 1.53 Million CAD | 97.515% |
Diagnamed Holdings Corp. | 426.38 Thousand CAD | 91.027% |
Pangenomic Health Inc. | 2.21 Million CAD | 98.274% |
Treatment.Com International Inc. | 1.47 Million CAD | 97.41% |
Unidoc Health Corp. | 2.38 Million CAD | 98.393% |